SCHEMBL574119

SCHEMBL574119

O=C(Nc1cccc(Cl)c1)c1cc(Cl)cc(Cl)c1OCl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX1 P51575 1/20 0.59
P2RX4 Q99571 1/20 0.59
P2RX7 Q99572 1/20 0.59
FADS1 O60427 4/20 0.58
SMN1; SMN2 Q16637 3/20 0.53
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
MAPT P10636 2/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
HTT P42858 1/20 0.51
HSPD1 P10809 1/20 0.50
HSPE1 P61604 1/20 0.50
KDM4E B2RXH2 1/20 0.50
STK39 Q9UEW8 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
GRM5 P41594 1/20 0.49
GRM4 Q14833 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8672680 0.81 PTGS1 (0.71) P2RX1P2RX4P2RX7FADS1SMN1; SMN2
SCHEMBL15778718 0.76 FADS1 (0.74) P2RX1P2RX4P2RX7FADS1SMN1; SMN2
SCHEMBL7760288 0.75 CHRNB2 (0.55) SMN1; SMN2RAB9AMEN1KMT2AMAPT
SCHEMBL15778670 0.75 FADS1 (0.68) P2RX1P2RX4P2RX7FADS1SMN1; SMN2
SCHEMBL11932152 0.75 P2RX1 (1.00) P2RX1P2RX4P2RX7FADS1
SCHEMBL5631068 0.75 P2RX1 (0.77) P2RX1P2RX4P2RX7FADS1SMN1; SMN2
SCHEMBL8469266 0.74 SMO (0.56) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL28017780 0.72 SMO (0.55) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL15779338 0.72 NPC1 (0.65) P2RX1P2RX4P2RX7FADS1SMN1; SMN2
SCHEMBL2701738 0.72 FADS1 (1.00) P2RX1P2RX4P2RX7FADS1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2313026-A1 ACTIVE DELIVERY SYSTEM FORMULATIONS Castle Beach, L.L.C. (US) 2011-04-27 EP claimed
US-20100040565-A1 ACTIVE DELIVERY SYSTEMS FORMULATIONS Castle Beach, LLC (US) 2010-02-18 US claimed
WO-2010019680-A1 ACTIVE DELIVERY SYSTEM FORMULATIONS HOMOLA ANDREW M (US) 2010-02-18 WO claimed
EP-0805672-B1 METHODS, COMPOSITIONS, AND DENTAL DELIVERY SYSTEMS FOR THE PROTECTION OF THE SURFACES OF TEETH HOMOLA ANDREW M (US) 2004-08-25 EP claimed
US-5665333-A Methods, compositions, and dental delivery systems for the protection of the surfaces of teeth PROVSEAL LLC 1997-09-09 US claimed
EP-3528776-B1 REDUCED-ETHANOL MOUTH RINSE FORMULATIONS KENVUE BRANDS LLC (US) 2025-11-26 EP disclosed
WO-2025067622-A1 CANNABIDIOL FOR USE IN ALLEVIATING XEROSTOMIA FERTIN PHARMA A/S (DK) 2025-04-03 WO disclosed
EP-4088716-B1 AN ORAL TABLET FOR INDUCED SALIVA GENERATION FERTIN PHARMA AS (DK) 2024-10-16 EP disclosed
US-11857653-B2 Method of providing an oral care benefit using a poorly-soluble calcium compound and fluoride JOHNSON & JOHNSON CONSUMER INC. (US) 2024-01-02 US disclosed
EP-3787604-B1 A TABLETED CHEWING GUM SUITABLE FOR ACTIVE PHARMACEUTICAL INGREDIENTS FERTIN PHARMA AS (DK) 2023-07-05 EP disclosed
US-11648186-B2 Coated particles and their uses JOHNSON & JOHNSON CONSUMER INC. (US) 2023-05-16 US disclosed
CN-109843255-B Ethanol-reducing mouthwash formulation 强生消费者公司 2023-02-28 CN disclosed
US-5145667-A Storage stable anticalculus toothpaste, noncationic bactericide, tripolyphosphate BEECHAM INC. (US) 1992-09-08 US disclosed
WO-1992004007-A1 COLOR CHANGE MOUTHRINSE BEECHAM, INCORPORATED (US) 1992-03-19 WO disclosed
US-5032386-A Dentistry COLGATE-PALMOLIVE COMPANY (US) 1991-07-16 US disclosed
EP-0161898-B1 DENTIFRICE COMPOSITIONS UNILEVER PLC (GB) 1990-11-07 EP disclosed
US-4749562-A ZINC SALT, ANTIMICROBIAL AGENT, H2O, SURFACTANT MIXED; FORMING LAMELLA LIQUID CRYSTAL PHASE LEVER BROTHERS COMPANY (US) 1988-06-07 US disclosed
US-4749561-A ZINC SALT ANTI-PLAQUE AGENT; LIQUID CRYSTAL SURFACTANT PHASE LAMELLA LEVER BROTHERS COMPANY (US) 1988-06-07 US disclosed
US-4656031-A SURFACTANT, ABRASIVE AND ANTI-PLAQUE AGENT LEVER BROTHERS COMPANY (US) 1987-04-07 US disclosed
EP-0161898-A2 Dentifrice compositions UNILEVER PLC (GB) 1985-11-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100040565-A1 ACTIVE DELIVERY SYSTEMS FORMULATIONS LIPA, MMP7, CTSA P2RX1 2757/4885P2RX4 3416/4885P2RX7 2458/4885
US-11648186-B2 Coated particles and their uses CD63, EPCAM, CD44 P2RX1 3481/4885P2RX4 3618/4885P2RX7 3227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.